Taro Net Income vs Ebit Analysis
TARO Stock | USD 42.73 0.01 0.02% |
Taro Pharmaceutical financial indicator trend analysis is much more than just breaking down Taro Pharmaceutical prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Taro Pharmaceutical is a good investment. Please check the relationship between Taro Pharmaceutical Net Income and its Ebit accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Taro Pharmaceutical Industries. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
Net Income vs Ebit
Net Income vs Ebit Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Taro Pharmaceutical Net Income account and Ebit. At this time, the significance of the direction appears to have very week relationship.
The correlation between Taro Pharmaceutical's Net Income and Ebit is 0.24. Overlapping area represents the amount of variation of Net Income that can explain the historical movement of Ebit in the same time period over historical financial statements of Taro Pharmaceutical Industries, assuming nothing else is changed. The correlation between historical values of Taro Pharmaceutical's Net Income and Ebit is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Income of Taro Pharmaceutical Industries are associated (or correlated) with its Ebit. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Ebit has no effect on the direction of Net Income i.e., Taro Pharmaceutical's Net Income and Ebit go up and down completely randomly.
Correlation Coefficient | 0.24 |
Relationship Direction | Positive |
Relationship Strength | Very Weak |
Net Income
Net income is one of the most important fundamental items in finance. It plays a large role in Taro Pharmaceutical financial statement analysis. It represents the amount of money remaining after all of Taro Pharmaceutical Industries operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Ebit
Most indicators from Taro Pharmaceutical's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Taro Pharmaceutical current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Taro Pharmaceutical Industries. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. As of the 17th of June 2024, Selling General Administrative is likely to drop to about 83.4 M. In addition to that, Discontinued Operations is likely to drop to about (404.5 K)
2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 293.1M | 268.3M | 305.0M | 238.5M | Total Revenue | 561.3M | 573.0M | 629.2M | 365.8M |
Taro Pharmaceutical fundamental ratios Correlations
Click cells to compare fundamentals
Taro Pharmaceutical Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Taro Pharmaceutical fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 2.3B | 2.4B | 2.2B | 2.1B | 2.2B | 2.3B | |
Other Current Liab | 192.1M | 605.9M | 355.9M | 314.2M | 316.4M | 332.3M | |
Total Current Liabilities | 222.7M | 676.3M | 432.1M | 385.5M | 361.1M | 379.2M | |
Total Stockholder Equity | 2.1B | 1.7B | 1.7B | 1.7B | 1.8B | 1.9B | |
Property Plant And Equipment Net | 210.0M | 205.5M | 199.7M | 190.1M | 217.6M | 124.8M | |
Net Debt | (511.8M) | (603.5M) | (248.9M) | (152.5M) | (362.9M) | (344.8M) | |
Retained Earnings | 2.7B | 2.3B | 2.4B | 2.4B | 2.8B | 2.9B | |
Cash | 513.4M | 605.2M | 251.1M | 154.5M | 362.9M | 186.1M | |
Non Current Assets Total | 808.7M | 936.0M | 838.5M | 799.1M | 858.7M | 901.6M | |
Non Currrent Assets Other | 3.5M | 4.3M | 6.8M | 83.1M | 82.5M | 86.6M | |
Cash And Short Term Investments | 1.1B | 1.0B | 820.7M | 850.3M | 879.4M | 923.3M | |
Net Receivables | 270.8M | 266.9M | 306.7M | 259.5M | 177.5M | 150.9M | |
Common Stock Shares Outstanding | 38.5M | 38.2M | 37.6M | 37.6M | 43.2M | 32.5M | |
Liabilities And Stockholders Equity | 2.3B | 2.4B | 2.2B | 2.1B | 2.2B | 2.3B | |
Non Current Liabilities Total | 8.8M | 35.1M | 32.8M | 19.1M | 8.0M | 7.6M | |
Inventory | 153.1M | 180.3M | 210.4M | 226.7M | 204.8M | 215.1M | |
Other Stockholder Equity | (459.1M) | (484.0M) | (509.0M) | (509.0M) | (458.1M) | (435.2M) | |
Total Liab | 231.5M | 711.4M | 464.9M | 404.7M | 369.1M | 219.5M | |
Total Current Assets | 1.5B | 1.5B | 1.3B | 1.3B | 1.3B | 1.4B | |
Short Term Debt | 1.5M | 1.7M | 2.2M | 2.0M | 2.2M | 2.1M | |
Intangible Assets | 21.7M | 19.8M | 60.1M | 76.1M | 87.6M | 91.9M | |
Accounts Payable | 28.9M | 61.2M | 68.2M | 68.5M | 44.7M | 73.5M | |
Other Current Assets | 8.8M | 12.9M | 14.2M | (1K) | 41.8M | 35.7M | |
Property Plant And Equipment Gross | 212.2M | 205.5M | 516.1M | 525.6M | 604.4M | 634.6M | |
Accumulated Other Comprehensive Income | (163.0M) | (151.6M) | (169.0M) | (175.0M) | (157.5M) | (149.6M) | |
Other Liab | 7.4M | 7.6M | 33.8M | 28.8M | 33.2M | 34.8M | |
Current Deferred Revenue | 237K | 7.6M | 5.8M | 903K | 812.7K | 772.1K | |
Other Assets | 121.3M | 156.6M | 139.0M | 1.0 | 1.15 | 1.09 | |
Short Term Investments | 595.4M | 418.5M | 569.6M | 695.8M | 516.4M | 324.5M | |
Property Plant Equipment | 190.7M | 193.9M | 187.6M | 181.4M | 208.6M | 186.0M | |
Net Tangible Assets | 1.9B | 2.1B | 1.7B | 1.6B | 1.9B | 1.9B | |
Long Term Investments | 459.6M | 557.2M | 435.2M | 404.9M | 465.6M | 292.1M | |
Non Current Liabilities Other | 2.7M | 1.6M | 4.1M | 2.7M | 3.1M | 2.0M | |
Net Invested Capital | 2.1B | 1.7B | 1.7B | 1.7B | 1.6B | 1.5B |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectAdditional Information and Resources on Investing in Taro Stock
When determining whether Taro Pharmaceutical offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Taro Pharmaceutical's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Taro Pharmaceutical Industries Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Taro Pharmaceutical Industries Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Taro Pharmaceutical Industries. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Taro Pharmaceutical. If investors know Taro will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Taro Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 1.181 | Earnings Share 1.43 | Revenue Per Share 16.74 | Quarterly Revenue Growth 0.125 | Return On Assets 0.0021 |
The market value of Taro Pharmaceutical is measured differently than its book value, which is the value of Taro that is recorded on the company's balance sheet. Investors also form their own opinion of Taro Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Taro Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Taro Pharmaceutical's market value can be influenced by many factors that don't directly affect Taro Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Taro Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Taro Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Taro Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.